<div class="bodyItems-wrapper">   <p class="yf-7hmkaz">Dec 19 (Reuters) - BioMarin Pharmaceutical (<a data-i13n="cpos:1;pos:1" href="https://finance.yahoo.com/quote/BMRN/" data-ylk="slk:BMRN;cpos:1;pos:1;elm:context_link;itc:0;sec:content-canvas" class="link ">BMRN</a>) said on Friday it would acquire Amicus Therapeutics (<a data-i13n="cpos:2;pos:1" href="https://finance.yahoo.com/quote/FOLD/" data-ylk="slk:FOLD;cpos:2;pos:1;elm:context_link;itc:0;sec:content-canvas" class="link ">FOLD</a>) for about $4.8 billion, expanding ​its presence in rare metabolic diseases.</p>   <p class="yf-7hmkaz">The drugmaker will ‌pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last ‌close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.</p>   <p class="yf-7hmkaz">The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for ⁠Fabry disease, which ‌is caused by a faulty gene that leads to a buildup of fatty substances in cells.</p>   <p class="yf-7hmkaz">Amicus ‍also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds ​up in the body's cells.</p>   <p class="yf-7hmkaz">Amicus also has U.S. rights ‌to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.</p>   <p class="yf-7hmkaz">BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.</p>   <p class="yf-7hmkaz">The company's total cash and ⁠investments at the end of ​September 30 were about $2 billion.</p>   <p class="yf-7hmkaz">The acquisition, ​which is expected to close in the second quarter of 2026, will add revenue immediately after the ‍transaction closes, ⁠BioMarin said.</p>   <section class="card variant-default tw-mb-6 yf-1fx3q76 elevation3"><form method="POST" class="yf-1fx3q76"><div class="fin-newsletter-img-wrapper yf-1fx3q76"> <img class="tw-bg-opacity-25 tw-h-full tw-w-full tw-object-cover yf-1ev0m0b" alt="Yahoo Finance Daily Movers" src="https://s.yimg.com/cv/apiv2/finance/newsletter/yfdm_v1.jpg" fetchpriority="auto" loading="lazy"></div> <div class="header-container yf-1fx3q76"><label for="dailyMovers-input"><header class="x-small tw-mb-0 mb-0 yf-1kayatz font-condensed"><h3 class="header  yf-1kayatz">   <span style="--base-variant: var(--font-label-md-emphasis); --tablet-variant: var(--font-label-md-emphasis); --desktop-variant: var(--font-label-md-emphasis); text-decoration: none; font-style: normal; text-transform: none; text-align: inherit;" class="text    yf-1xj3fin">Sign up for Yahoo Finance Daily Movers </span></h3> </header> </label> <span class="newsletter-info yf-1qiord2"><span class="container tw-flex tw-items-center tw-py-4 -tw-my-4 yf-1ouvapf"><div aria-hidden="true" class="icon fin-icon inherit-icn sz-x-large  yf-sv6wwp"><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 24 24"><path d="M11 7h2v2h-2zm0 4h2v6h-2zm1-9C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2m0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8"></path></svg> </div> <div class="tooltip al-top tw-z-10  yf-1ouvapf" role="tooltip"><div class="arrow yf-1ouvapf"></div>        <span style="--base-variant: var(--font-label-sm-reg); --tablet-variant: var(--font-label-sm-reg); --desktop-variant: var(--font-label-sm-reg); color: var(--color-text-icon-secondary, inherit); text-decoration: none; font-style: normal; text-transform: none; text-align: inherit;" class="text    yf-1xj3fin" slot="content">By subscribing, you are agreeing to Yahoo's 
                <a class="fin-disclaimer-link" data-ylk="elm:corp;itc:0;elmt:newsletter;pkgt:newsletter;sec:newsletter" href="https://legal.yahoo.com/us/en/yahoo/terms/otos/index.html" rel="noreferrer noopener" target="_blank">
                    Terms
                </a>
             and 
                <a class="fin-disclaimer-link" data-ylk="elm:corp;itc:0;elmt:newsletter;pkgt:newsletter;sec:newsletter" rel="noreferrer noopener" href="https://legal.yahoo.com/us/en/yahoo/privacy/index.html" target="_blank">
                    Privacy Policy
                </a>
             </span></div></span> </span></div> <div class="fin-newsletter-input-wrapper yf-1fx3q76"><div class="input yf-1fx3q76"><div aria-hidden="true" class="icon fin-icon primary-icn sz-x-large mail-icon yf-sv6wwp"><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 24 24"><path d="M22 6c0-1.1-.9-2-2-2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2zm-2 0-8 5-8-5zm0 12H4V8l8 5 8-5z"></path></svg> </div> <input id="dailyMovers-input" name="email" placeholder="Email address" required type="email" class="yf-1fx3q76"></div> <button class="primary-btn fin-size-medium fin-newsletter-button tw-justify-center    rounded   yf-r7dg9i" data-ylk="elm:subscribe;slk:Subscribe;itc:0;elmt:newsletter;pkgt:newsletter;sec:newsletter" type="submit" data-testid="newsletter-btn"> Subscribe </button></div>  </form></section>   <p class="yf-7hmkaz">The deal is also expected to add to adjusted profit in the first 12 months after close ⁠and be substantially accretive beginning in 2027, the company said.</p>   <p class="yf-7hmkaz">(Reporting by Christy ‌Santhosh and Sriparna Roy in Bengaluru; Editing by ‌Leroy Leo and Maju Samuel)</p>   </div>

Dec 19 () - BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding ​its presence in rare metabolic diseases.

BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet

Vaccine hesitancy isn’t a moral failure – it’s a property of a system in which people must balance personal and collective interests.

Game theory explains why reasonable parents make vaccine choices that fuel outbreaks

“I couldn’t just sit there and continue to argue and see they’re not changing their minds,” Haskel told the Post about the marathon discussions on the bill taking place in the Knesset. After three days on the road and over 80 kilometers on foot, Deputy Foreign Minister Sharren Haskel (New Hope) spoke to The Jerusalem Post on Wednesday about her march this week in protest of the government’s haredi (ultra-Orthodox) draft bill, which she said endangers Israel’s future.

80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill

Some hospitals are taking a dramatic step to save mothers and babies after studies have shown too many doctors fail to follow guidelines for preventing preeclampsia.

Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests

March ICE NY cocoa (CCH26 ) on Thursday closed down -44 (-0.74%), and March ICE London cocoa #7 (CAH26 ) closed down -24 (-0.55%). Cocoa prices settled lower on Thursday, with NY cocoa falling to a 1-week low. Favorable weather in West Africa is expected to boost yields and supply,...

Cocoa Prices Settle Lower on Expectations of Adequate Supplies

Polish Foreign Minister Radosław Sikorski said on Wednesday that Warsaw was open to the possible deployment of German troops in Poland as part of efforts to secure a ceasefire in Ukraine. German soldiers have been stationed in Poland for years as part of various NATO missions, Sikorski said, adding that the presence of Bundeswehr troops on Polish soil would therefore be nothing new.

Poland open to German troops to help secure Ukraine ceasefire

A cellular breakdown in the lungs determination can feel overwhelming, with various treatment courses that appear to be overpowering from the outset. As clinical progressions have


Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs


Ukrainian President Volodymyr Zelensky has removed his former chief of staff Andriy Yermak from the National Security Council amid a sprawling corruption investigation that has rocked Kiev. Yermak is also no longer a member of the Stavka, the high command of Ukraine's armed forces, according to two presidential decrees published on Friday.

Zelensky confidant dismissed from further posts amid bribery scandal

On Episode 192 of This Week In Space, Rod Pyle and Tariq Malik looks forward to 2026, which promises to be the most exciting year in the new space age yet!

This Week In Space podcast: Episode 192 — Space, 2026!

There are billions of dollars in it for companies able to kickstart mining operations, even if such returns are still years away.

The race to mine the moon is on – and it urgently needs some clear international rules

In the realm of gaming and mechanical advancement, augmented reality games act as the passages that transport us into vivid


Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game


Samples collected from the asteroid Bennu are continuing the shed light on the origins of the solar system and how life developed on Earth, scientists say.

Bennu asteroid samples provide clues about solar system origins and 'space gum'

An alleged Palestine Action member has told jury the group "didn't want any harm" during a break-in.

Violence 'never part' of break-in plan, court told

Taking part in outside exercises is a phenomenal way for seniors to remain dynamic, mingle, and appreciate nature. These exercises can


Partake in the Outside: Senior-Accommodating Exercises for 2024


"The family appreciates all prayers at this time," according to a statement.